Case studies reveal the gap between research progress and clinical readiness. In these stories, earlier CMC involvement might have saved resources and staved off delays.
- Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
- What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
- How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
- Can Peptide Mapping Predict Intact Antibody PTM Distributions?
- The EU Overhauls Pharma Laws: What You Need To Know
- An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
- Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
GUEST COLUMNISTS
-
Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.
-
What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.
-
How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
Europe's glass manufacturers, including those making pharmaceutical lab glassware, have experienced a series of energy shocks. Many have adopted sustainability practices.
-
The EU Overhauls Pharma Laws: What You Need To Know
On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.
-
Can Peptide Mapping Predict Intact Antibody PTM Distributions?
Peptide mapping quantifies modification at individual sites, but the same site-level results can correspond to different distributions across intact molecules.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
-
Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
Geopolitical shocks are reshaping outsourced pharmaceutical testing. Learn how procurement teams can strengthen resilience and protect continuity.
BIOSIMILAR WHITE PAPERS
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
Aggregation In Antibody-Drug Conjugates: Causes And Mitigation9/1/2025
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
ADC Manufacturing: Practices, Challenges, And The Road Ahead6/15/2026
ADCs are advancing quickly, but manufacturing complexity is rising just as fast. Key challenges in scale-up, regulation, and costs are reshaping how the next generation of therapies will be delivered.
-
Why Choose Robotic Processing For Small Batch Aseptic Filling1/9/2026
Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.
-
How Lipid Nanoparticles Enable Next-Gen Delivery10/20/2025
Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.
-
Innovation In Filtration3/18/2025
Filtration removes contaminants to ensure safety and is essential in various applications, from lab-scale tasks to GMP production. Explore how its simplicity and reliability make it indispensable.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- AEON Biopharma Submits IND For Comparative Pharmacodynamic Study Of ABP-450
- New Biosimilar For Patients With Certain HER2-Positive Breast Cancer Is Approved By Anvisa
- GlycoNex Announces Japanese Regulatory Submission For Denosumab Biosimilar SPD8
- New Real-World Evidence Presented By Organon At The American College Of Rheumatology (ACR) Annual Meeting Evaluated A Large-Scale Switch To HADLIMA (Adalimumab-BWWD) Across United States Veterans Affairs Healthcare System
- Samsung Bioepis Presents Phase 3 Study Of Proposed Pembrolizumab Biosimilar At SITC 2026
- CVS Caremark Is Expanding Access And Affordability With Biosimilars
- Bio-Thera Announces NMPA Approval Of BAT2506, The First Golimumab Biosimilar Approved In China
- Teva And Samsung Bioepis Announce Agreement To Commercialize Two FDA-Approved Biosimilars In The U.S.
NEWSLETTER ARCHIVE
- 11.12.26 -- 5 Steps To Achieving Your Biosimilar Milestones On Time
- 11.05.26 -- 7 Decisions To Make Before MES Configuration
- 10.29.26 -- How Indian Biosimilar Companies Are Poised To Succeed
- 10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You
- 10.22.26 -- Reduce risk. Move Annex 1 forward.
